Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21484726 | 0.85 | ABL1 (0.73) | ABL1KDM4EMAPTMEN1NPC1 | |
| SCHEMBL2455704 | 0.84 | ABL1 (0.72) | ABL1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL21484720 | 0.83 | ABL1 (0.71) | ABL1KDM4EMAPTMEN1NPC1 | |
| SCHEMBL21484613 | 0.83 | ABL1 (0.71) | ABL1KDM4EMAPTMEN1NPC1 | |
| SCHEMBL21484800 | 0.81 | KMT2A (0.69) | ABL1KDM4EMAPTMEN1NPC1 | |
| SCHEMBL21484850 | 0.81 | ABL1 (0.69) | ABL1KDM4EMAPTMEN1NPC1 | |
| SCHEMBL21484709 | 0.81 | ABL1 (0.69) | ABL1KDM4EMAPTMEN1NPC1 | |
| SCHEMBL21484734 | 0.81 | ABL1 (0.69) | ABL1KDM4EMAPTMEN1NPC1 | |
| SCHEMBL21484695 | 0.81 | ABL1 (0.69) | ABL1KDM4EMAPTMEN1NPC1 | |
| SCHEMBL21484835 | 0.81 | ABL1 (0.68) | ABL1KDM4EMAPTMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2022-09-27 | — | — | US | disclosed |
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-03-10 | — | — | US | disclosed |
| CN-112351983-A | Substituted propionamides as inhibitors of nucleases | 马萨里克大学 | 2021-02-09 | — | — | CN | disclosed |
| EP-3556756-B1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2020-10-07 | — | — | EP | disclosed |
| EP-3556756-B1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2020-10-07 | — | — | EP | disclosed |
| WO-2019201867-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201867-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
| EP-3556756-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | Masarykova univerzita (CZ) | 2019-10-23 | — | — | EP | disclosed |
| EP-3556756-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | Masarykova univerzita (CZ) | 2019-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | DNASE1, RNASEH1, FEN1 | ABL1 4272/4885KDM4E 1639/4885MAPT 1351/4885 |
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | DNASE1, RNASEH1, FEN1 | ABL1 4272/4885KDM4E 1639/4885MAPT 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.